• Corexa Pharmacy, a unit of DataMeds AI’s wholly owned Corexa Health subsidiary, posted preliminary September 2026 revenue above $1 million.
• Revenue rose more than 66% from July 2026, following completion of the Corexa Pharmacy rebrand early in Q3 2026.
• Management flagged growth tied to prescription volume and adjunct product sales, with emphasis on GLP-1 therapies and Long COVID patients.
• Corexa Pharmacy is being upgraded as a flagship site for the Health Lives Here initiative, aimed at scaling across Corexa Health’s 6,500-pharmacy network.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DataMeds AI Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610010600ACCESSWRNAPR_____1230007) on October 01, 2026, and is solely responsible for the information contained therein.